drugset / Trial / NCT06563778
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
RandomizedParallel-groupOpen-labelTreatment
Summary
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor. This open label, randomized, phase 2 study aims to evaluate the efficacy of Chidamide+Decitabine plus Anti-PD-1 Antibody and Brentuximab Vedotin + Bendamustine plus Anti-PD-1 Antibody in transplant-ineligible or refused transplant diagnosed R/R cHL. The primary objective of the study is to evaluate progression-free survival.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2026-09-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | 70 mg/m2 | — |
| Comparator | Bendamustine | Small molecule | 90 mg/m2 | — |
| Comparator | Brentuximab Vedotin | Monoclonal antibody | 1.2 mg/kg | — |
| Comparator | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | — |
| Subject | Decitabine | Small molecule | 10 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |